New diagnostic and treatment targets in cartilage tumours
Official title: Finding New Diagnostic and Therapeutic Targets in Cartilaginous Tumours
Run by St. Anne's University Hospital Brno, Czech Republic · NCT07315542 · Data updated 2026-11-12
This project will test whether IDH1/2 gene changes and specific microRNA signals in tumour tissue and blood can help diagnose and guide treatment for people with cartilage tumours including chondrosarcoma.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | St. Anne's University Hospital Brno, Czech Republic Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Brno, South Moravian) |
| Status | Recruiting |
| Started | May 1, 2025 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2028 |
| Registry record updated | January 5, 2026 |
| Trial ID | NCT07315542 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
People with histologically confirmed cartilaginous tumours (enchondroma, atypical cartilaginous tumour/grade 1, conventional grade 2–3 chondrosarcoma, dedifferentiated or other variants) who are treated and/or followed at St. Anne's University Hospital Brno are ideal candidates.
✕Probably not a fit
Patients who do not have sufficient or usable tissue samples, or who are not treated/followed at the Brno center, are not eligible and would not benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational project collects tumour tissue and blood (liquid biopsy) from patients with cartilaginous tumours to search for molecular biomarkers. Investigators will analyze tumour DNA for IDH1/2 mutations and profile non-coding microRNAs, with molecular validation in the laboratory. Results will be compared with pathology, imaging, and clinical outcomes to help distinguish benign cartilage lesions from low-grade and higher-grade chondrosarcoma and from other bone sarcomas. The work is conducted at St. Anne's University Hospital Brno in collaboration with Masaryk University and includes biobanking and molecular validation steps.
Why it matters
Potential benefit: If successful, these markers could improve diagnostic accuracy, better predict tumour behavior, and point to targeted treatment options for patients with chondrosarcoma.
How similar studies have gone: IDH1/2 mutations are already known to be common and diagnostically useful in central chondrosarcoma and have been explored therapeutically in other cancers, while microRNA-based markers remain more exploratory.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria * Histologically confirmed cartilaginous (chondroid) tumour * Diagnosis includes one of the following entities (as available and eligible): * Enchondroma * Atypical cartilaginous tumour / Grade 1 chondrosarcoma (ACT/G1) * Conventional chondrosarcoma (Grade 2-3) * Dedifferentiated chondrosarcoma * Other rare chondrosarcoma variants (e.g., mesenchymal, clear-cell), if present in the cohort * Patients treated and/or followed at the First Department of Orthopaedic Surgery, St. Anne's University Hospital Brno Exclusion Criteria * Insufficient, degraded, or otherwise unusable tissue samples
Where it's running
-
First Department of Orthopaedic Surgery, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czechia
Brno, South Moravian, Czechia Recruiting
Study contacts
- Principal investigator: Tomáš Tomáš, Assoc.Prof., M.D., Ph.D. — Faculty of Medicine, Masaryk University, Brno, 60200, Czechia
- Study coordinator: Vasileios Apostolopoulos, M.D., Ph.D.
- Email: vasileios.apostolopoulos@fnusa.cz
- Phone: +420722101065
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.